E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 23.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10084272 |
E.1.2 | Term | SARS-CoV-2 infection |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine if S-217622 will reduce the time to sustained symptom resolution through Day 29 among outpatient adults with mild and moderate COVID-19 starting intervention within 3 days of symptom onset. Time to sustained symptom resolution is defined as the time from start of study intervention to the first day of 2 consecutive days with complete resolution of COVID-19 symptoms on participant selfassessment AND alive and without hospitalization for any reason by Day 29 and will be compared using restricted mean symptom duration up to Day 28, which is the last timepoint at which the outcome can be achieved. Hospitalization is defined as ≥24 hours of acute care, in a hospital or similar acute care facility, including emergency rooms, urgent care clinics, or facilities instituted to address medical needs of those with COVID-19 |
|
E.2.2 | Secondary objectives of the trial |
To determine whether S-217622 reduces COVID-19- related hospitalization (adjudicated) and all deaths regardless of occurrence outside of hospital or during hospitalization (not adjudicated) through Day 29 among outpatient adults with SARS-CoV-2 starting intervention within 3 days of symptom onset. To determine if S-217622 will reduce the time to sustained symptom resolution through Day 29 among all outpatient adults with SARS-CoV-2. To determine the effect of S-217622 compared with placebo on: - To determine the change from baseline in quantitative log10 SARSCoV-2 RNA levels by PCR on NP swab at Day 4 among all outpatient adults with SARS-CoV-2 (and when starting intervention within 3 days of symptom onset). - on the occurrence of persistent and/or late-onset symptoms of COVID19 at Week 12 among all outpatient adults with SARS-CoV-2 (and when starting intervention within 3 days of symptom onset).
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
For all participants -Ability and willingness of participant to provide informed consent prior to initiation of any study procedures. -Age ≥18 years. -Documentation of laboratory-confirmed active SARS-CoV-2 infection, as determined by a nucleic acid (e.g., reverse-transcriptase PCR) or antigen test from any respiratory tract specimen (e.g., oropharyngeal, NP or nasal swab, or saliva) collected ≤72 hours (3 days) prior to randomization. -Participants are expected to begin study intervention ≤3 days from selfreported date of onset of any of the COVID-19-related symptoms as described in the study protocol. For high-risk participants (excluded in the US) Participants at higher risk of progression to severe COVID-19 are defined as follows: Age ≥65 years Age ≥18 with 1 of the following: o Obesity (body mass index [BMI] ≥30 kg/m2). Note: BMI is rounded to the nearest whole number, for example 29.5 kg/m2 is rounded to 30 kg/m2. o Diabetes mellitus o Hypertension requiring daily prescribed therapy o Cardiovascular disease requiring daily prescribed therapy or congenital heart disease o Chronic lung disease (e.g., chronic obstructive pulmonary disease [COPD], moderate to severe asthma, interstitial lung disease, cystic fibrosis, pulmonary hypertension) requiring daily prescribed therapy o Chronic kidney disease, defined as known current kidney impairment with a creatinine clearance (CrCl) or estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2 within the past 12 months prior to randomization, as long as the participant does not have known CrCl <30 mL/min by Cockcroft-Gault or require dialysis (see Exclusion Criterion 4.1.2.9) o Down syndrome o Sickle cell disease o One of the following immunocompromising conditions or immunosuppressive treatments: Receiving chemotherapy or other therapies for cancer Hematologic malignancy (active or in remission) History of a hematopoietic stem cell or a solid organ transplant HIV infection: not on antiretroviral therapy or with CD4+ cell count <200 cells/mm3 Combined primary immunodeficiency disorder Taking immunosuppressive medications (e.g., drugs to suppress rejection of transplanted organs or to treat rheumatologic and gastrointestinal conditions, such as anti-tumor necrosis factor agents, mycophenolate, and rituximab) Note: Current use of some corticosteroids is exclusionary, due to concern for possible DDI with S-217622. See Section 5.4.2 for prohibited medications. For standard-risk participants Only standard-risk participants will be enrolled at US sites. Participants at standard risk for progression to severe COVID-19 are defined as ≥18 to <65 years of age and meeting all criteria from Sections 4.1.1.1 to 4.1.1.13 with none of the risk factors listed above |
|
E.4 | Principal exclusion criteria |
-History of hospitalization for the current SARS-CoV-2 infection (i.e., prior hospitalization for a prior episode of SARS-CoV-2 infection is allowable). -For the current SARS-CoV-2 infection, any positive SARS-CoV-2 molecular (nucleic acid) or antigen test from any respiratory tract specimen (e.g., oropharyngeal, NP or nasal swab, or saliva) collected >72 hours (3 days) prior to randomization. -Participants with reinfection, defined as prior SARS-CoV-2 infection that began >90 days prior to the current onset of symptoms with interval resolution of symptoms are eligible as long as the current infection has not been present for more than 3 days prior to randomization. -Current need for hospitalization or immediate medical attention in the opinion of the investigator. -Current use of any medications prohibited with the study intervention, as described in Section 5.4.2 of the protocol. Individuals who have used Paxlovid or any other oral, inhaled, or injectable medication intended to treat the current SARS-CoV-2 infection before randomization are excluded. After randomization, locally available SARS-CoV-2 treatment (including but not limited to molnupiravir, mAbs, outpatient IV remdesivir, convalescent plasma, inhaled budesonide, favipiravir, and fluvoxamine) will be permitted, as long as there are no concerns for DDIs as outlined in Section 5.4.2. of the protocol Note: Paxlovid use for a prior episode of COVID-19 is permitted. -Receipt of any investigational treatments for the current episode of SARS-CoV-2 at any time prior to randomization is exclusionary. NOTE: This does not include drugs approved for other uses and taken for those indications or COVID-19 vaccines. NOTE: Use of locally authorized or approved therapies to prevent COVID- 19, such as mAbs given solely to prevent COVID-19, are not exclusionary. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Symptom duration for all targeted symptoms (including those occurring prior to COVID-19 infection): Time (days) from start of S-217622 or placebo (Day 1) until sustained resolution and being alive and without hospitalization for any reason by Day 29. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
From start of S-217622 or placebo (Day 1) until sustained resolution and being alive and without hospitalization for any reason by Day 29. |
|
E.5.2 | Secondary end point(s) |
Key secondary virologic outcome: change from baseline in quantitative log SARS-Cov-2 RNA levels by PCR on NP swab at Day 4 among outpatient adults with SARS-CoV-2. Key secondary clinical outcome: The composite of COVID-19-related hospitalization (adjudicated) and all deaths regardless of occurrence outside of hospital or during hospitalization (not adjudicated) through Day 29 among outpatient adults with SARS-CoV-2 starting intervention within 3 days of symptom onset. Key secondary clinical outcome: The proportion of participants with persistent and/or late-onset symptoms of COVID-19 at Week 12 based on participants' assessments of the 5 symptoms specified by the WHO (fatigue, shortness of breath/difficulty breathing, difficulty with concentration/ thinking, difficulty reasoning/solving problems, and memory loss) plus taste disturbance and smell disturbance among outpatient adults with SARS-CoV-2 starting intervention within 3 days of symptom onset. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
virologic outcome: Day 4
clinical outcome: Day 1 to Day 29 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 5 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Colombia |
Egypt |
Ghana |
Malawi |
Philippines |
Uganda |
Puerto Rico |
Brazil |
India |
Japan |
Kenya |
Mexico |
Pakistan |
South Africa |
Thailand |
United States |
Poland |
Türkiye |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 4 |